Insider buying indicates management’s conviction in undervalued shares ahead of multiple near-term catalysts: NEO100: interim data readout – expected within ~4 months NEO212: expects Type B End-of-Phase FDA meeting to align on a potential pivotal, registrational Phase 2 study – within the next 4 weeks CALABASAS, Calif., April 14, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies […]

CALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced financial results for the quarter and year ended December 31, 2025, and provided an update on recent operational achievements and […]